About

Alvion is a science oriented pharmaceutical company developing and manufacturing non infringing generic medicines. Collaborating with state of the art R&D centers in Greece and internationally, Alvion is a private and independent company focusing in R&D, Intellectual Property, Quality, Regulatory, manufacturing and supply of generic and added value products delivering an exceptional track record across the industry. Among the best "Greek brands in Pharma" across the world. By developing a best-in-class international pharmaceutical company, Alvion is launching its portfolio of products and services across EU, MENA, Canada, Australia, South Africa and Latin America partnering and supplying with some of the most well-known pharmaceuticals companies. From the Business Development point of view, Alvion is signing exclusive agreements on offering rights of the Intellectual Property as well as Supplying the final products in each company in various markets. Investing via the organic growth in products and people is the number one priority, aiming to establish an R&D laboratory center within few years time and in the long run a state of the art manufacturing facility becoming one of the fastest growing pharmaceutical companies in Europe.

Solution & Product

Whilst offering the competitive advantages that fit Alvion Pharmaceuticals business strategy, namely a) low Costs (both fixed and variable), b) Flexibility c) Partner/Business Development, d) R&D e) PEOPLE, Alvion Pharmaceuticals is targeting to gain market share starting with its first blockbuster generic products. Action Plan: •Three years development plan for 3 million euros in products and IP in partnership with large Greek and foreign pharmaceutical companies/laboratories. •Following the first milestone to develop/establish an R&D center attracting Greek talents to reinvest in products and pipeline for 2023-2027. •Build gradually a manufacturing facility to in-house all the above product and the future products of Alvion. •In the meantime, to exhibit in the largest pharma events, Alvion Pharmaceuticals stand promoting its own developments whereas Alvion already has a number of international agreements with large pharmaceutical companies suppling them on an exclusive basis. •Gradually open a UK office for its Business Development Team. - Specifically Product portfolio and pipeline, Alvion has and develops a range of products focusing in Cardiovascular solid form therapies and simultaneously we are investing in Diabetes, Urology and Central Nervous System.

Innovation & Scalability

Alvion is developing in partnership with R&D centers and manufacturers a number of products and services. These products and services are offered across the world to pharmaceutical companies. While the company is growing it is offering more products to more partners by expanding its business and operations, being fully extrovert company "exporting" Greek pharmaceutical know how. As a result the business model is scalable as it is both innovative and industrial. Alvion has already established agreements resulting to growth plans strategy for the next few years. We have very high expectations on the growth of the company by the already signed agreements but most importantly by the agreements that Alvion is negotiating with the multinational pharmaceutical companies.

Traction & achievements

Alvion has gained access by investing in products, establishing a number of multinational synergies. Being considered one of the new pharma companies in EU, we have achieved within few years a number of important commercial milestones becoming a fully extrovert company, creating an exceptional track record. Few years ago, Alvion has also been selected from Endeavor Opap Forward companies selection in 2016 as selected in twenty best companies out of 500 plus that registered in the program.

Team & Why Us

Both Greek and international teams represent the activities of Alvion, investing in Greek technologies of R&D, exporting mainly from Greek and foreign production facilities. CEO: John Bouros Business Development: Ciaran Burke based in Ireland with 25+ years experience in global business development. Regulatory Affairs: Sofia Koutzi, scientist returning from UK following higher education Marina Ioannidou, Project manager Panagiotis Kourounis: Financial expert Alvion is committed to deliver a solid and profitable business plan, growing significantly the years to come. Lastly but not least, Alvion Pharmaceuticals P:.C. is aiming to become synonymous with the Greek International pharmaceutical success raising even higher the barrier of the Greek pharma industry.

Funding Needs

Alvion is investing in high technology pharmaceutical products. Its investment plan for the next two years is approximately 2.0-2.5 Million Euros on the product development and infrastructure. The funds should be available via three methodologies a) organically from the profits of the company, b) from loans and c) from government granting for R&D and infrastructure. A matrix of these three forms shall provide the opportunity to Alvion Pharmaceuticals to grow in the level of 50+ Million Euros.